Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 1998

View Archived Issues

Company Profile: Ascent

Weekly fish consumption might reduce the risk of sudden cardiac death in men

Interleukin-1: a potential target for the treatment of atherosclerosis

Sonus: Q4 and FY 1997 highlights

Centocor: FY 1997 highlights

P&U receives three-year marketing exclusivity for Rogaine Extra Strength

NeoPharm to pursue FDA approval of Neomark

Roche and deCODE Genetics form genomics collaboration

DEHOP enters phase I for NHL

Icos: Q4 and FY 1997 highlights

BioCryst: Q4 and FY 1997 highlights

Dopamine transporter ligands prepared at CIS Bio

Anticoagulant apoB-100 fragment discovered at Royal Free Hospital

Boehringer Mannheim develops new agents for diabetes

Antiobesity and antidiabetic compounds claimed by American Home Products

Asta's new immunophilin ligands

Glaxo Wellcome's new NRTI highlighted at AIDS conference

Corlopam finally on the market -- U.S. is country of first launch

CV Therapeutics, Cleveland Clinic Foundation collaborate on study of CVT-313

Ilex initiates phase I testing of intoplicine

Promising laboratory findings and phase I results reported for Leukine

Migranal Nasal Spray now available in U.S.

First results described for novel aromatase inhibitor in phase I

Nitric oxide as a target in stroke therapy

Bristol-Myers Squibb and NeuroSearch expand agreement for Parkinson's drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...